



Dynavax Technologies Corporation
Investor Relations Department
2929 Seventh Street
Berkeley, CA 94710
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: DVAX

Last Trade:	19.25
Trade Time:	4:00 PM ET Dec 15, 2017
Change:	0.50 (+2.667%)
Day Range	18.65 - 19.65
52-Week Range	3.70 - 24.45
Volume	3,652,272

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Dynavax is a clinical-stage immunology company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax is developing product candidates for use in m... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Dec 5, 2017*
[Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635\(c\)\(4\)](#)
- Nov 27, 2017*
[Dynavax to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference](#)
- Nov 9, 2017*
[Dynavax Announces FDA Approval of HEPLISAV-B\(TM\) for Prevention of Hepatitis B in Adults](#)
- Nov 3, 2017*
[Dynavax Reports Third Quarter 2017 Financial Results](#)
- Oct 19, 2017*
[Dynavax Initiates Clinical Trial in Non-Small Cell Lung Cancer with a Novel Inhaled TLR9 Agonist in Combination with Anti-PD-1 Therapy](#)

Financials [\[View all \]](#)

- [Third Quarter Financial Results](#)
- Mar 13, 2017*
[Annual Report \(10-K\)](#)
- Jul 10, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Nov 3, 2017*
[Quarterly Report \(10-Q\)](#)
- Aug 7, 2017*
[Quarterly Report \(10-Q\)](#)
- May 8, 2017*
[Quarterly Report \(10-Q\)](#)